Literature DB >> 31326506

Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders.

Ashleigh L Osborne1, Nadia Solowij2, Ilijana Babic3, Jeremy S Lum1, Xu-Feng Huang4, Kelly A Newell1, Katrina Weston-Green5.   

Abstract

Cognitive impairment is a major source of disability in schizophrenia and current antipsychotic drugs (APDs) have minimal efficacy for this symptom domain. Cannabidiol (CBD), the major non-intoxicating component of Cannabis sativa L., exhibits antipsychotic and neuroprotective properties. We recently reported the effects of CBD on cognition in male offspring of a maternal immune activation (polyinosinic-polycytidilic acid (poly I:C)) model relevant to the aetiology of schizophrenia; however, the effects of CBD treatment in females are unknown. Sex differences are observed in the onset of schizophrenia symptoms and response to APD treatment. Furthermore, the endogenous cannabinoid system, a direct target of CBD, is sexually dimorphic in humans and rodents. Therefore, the present work aimed to assess the therapeutic impact of CBD treatment on behaviour and neurochemical signalling markers in female poly I:C offspring. Time-mated pregnant Sprague-Dawley rats (n = 16) were administered poly I:C (4 mg/kg; i.v.) or saline (control) on gestational day 15. From postnatal day 56, female offspring received CBD (10 mg/kg, i.p.) or vehicle treatment for approximately 3 weeks. Following 2 weeks of CBD treatment, offspring underwent behavioural testing, including the novel object recognition, rewarded alternation T-maze and social interaction tests to assess recognition memory, working memory and sociability, respectively. After 3 weeks of CBD treatment, the prefrontal cortex (PFC) and hippocampus (HPC) were collected to assess effects on endocannabinoid, glutamatergic and gamma-aminobutyric acid (GABA) signalling markers. CBD attenuated poly I:C-induced deficits in recognition memory, social interaction and glutamatergic N-methyl-d-aspartate receptor (NMDAR) binding in the PFC of poly I:C offspring. Working memory performance was similar between treatment groups. CBD also increased glutamate decarboxylase 67, the rate-limiting enzyme that converts glutamate to GABA, and parvalbumin protein levels in the HPC. In contrast to the CBD treatment effects observed in poly I:C offspring, CBD administration to control rats reduced social interaction, cannabinoid CB1 receptor and NMDAR binding density in the PFC, suggesting that CBD administration to healthy rats may have negative consequences on social behaviour and brain maturation in adulthood. Overall, the findings of this study support the therapeutic benefits of CBD on recognition memory and sociability in female poly I:C offspring, and provide insight into the neurochemical changes that may underlie the therapeutic benefits of CBD in the poly I:C model.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain; Cannabidiol; Cannabinoid; Cognition; GABA; Glutamate; Maternal immune activation; Schizophrenia

Year:  2019        PMID: 31326506     DOI: 10.1016/j.bbi.2019.07.018

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  8 in total

Review 1.  Cannabidiol for the treatment of autism spectrum disorder: hope or hype?

Authors:  João F C Pedrazzi; Frederico R Ferreira; Danyelle Silva-Amaral; Daniel A Lima; Jaime E C Hallak; Antônio W Zuardi; Elaine A Del-Bel; Francisco S Guimarães; Karla C M Costa; Alline C Campos; Ana C S Crippa; José A S Crippa
Journal:  Psychopharmacology (Berl)       Date:  2022-07-29       Impact factor: 4.415

Review 2.  Translational opportunities in the prenatal immune environment: Promises and limitations of the maternal immune activation model.

Authors:  Melissa D Bauman; Judy Van de Water
Journal:  Neurobiol Dis       Date:  2020-04-09       Impact factor: 5.996

3.  Cannabis Vapor Exposure Alters Neural Circuit Oscillatory Activity in a Neurodevelopmental Model of Schizophrenia: Exploring the Differential Impact of Cannabis Constituents.

Authors:  Bryan W Jenkins; Shoshana Buckhalter; Melissa L Perreault; Jibran Y Khokhar
Journal:  Schizophr Bull Open       Date:  2021-11-20

4.  Time of Day-Dependent Alterations in Hippocampal Kynurenic Acid, Glutamate, and GABA in Adult Rats Exposed to Elevated Kynurenic Acid During Neurodevelopment.

Authors:  Courtney J Wright; Katherine M Rentschler; Nathan T J Wagner; Ashley M Lewis; Sarah Beggiato; Ana Pocivavsek
Journal:  Front Psychiatry       Date:  2021-09-17       Impact factor: 4.157

5.  Prenatal Poly I:C Challenge Affects Behaviors and Neurotransmission via Elevated Neuroinflammation Responses in Female Juvenile Rats.

Authors:  Yueqing Su; Jiamei Lian; James Hodgson; Wenchang Zhang; Chao Deng
Journal:  Int J Neuropsychopharmacol       Date:  2022-02-11       Impact factor: 5.176

6.  Effect of long-term cannabidiol on learning and anxiety in a female Alzheimer's disease mouse model.

Authors:  Rose Chesworth; David Cheng; Chloe Staub; Tim Karl
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

Review 7.  From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia.

Authors:  Kurt Leroy Hoffman
Journal:  Front Psychiatry       Date:  2021-07-05       Impact factor: 4.157

Review 8.  [Neurodevelopment and cannabis].

Authors:  M-O Krebs; F Demars; A Frajerman; O Kebir; T Jay
Journal:  Bull Acad Natl Med       Date:  2020-04-17       Impact factor: 0.144

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.